Kalah Auchincloss, JD, MPH

Kalah leverages her experience at FDA, on Capitol Hill, and in the private sector to advise clients on regulatory policy, compliance, enforcement, and other actions.

Before joining ELIQUENT, Kalah spent six years at the FDA, where she served in several senior leadership roles across the agency, including: Deputy Chief of Staff; FDA Detailee to the Senate HELP Committee, working on the 21st Century Cures Act and other FDA-related legislation; Acting Director of FDA’s Center for Drug Evaluation and Research (CDER) Office of Unapproved Drugs and Labeling Compliance; and Regulatory Counsel in CDER’s Office of Regulatory Policy. Learn more about Kalah

Brian M. Mayhew, MA, MBA

Brian brings more than two decades of experience to his role at ELIQUENT Life Sciences where he leads the firm’s regulatory policy and intelligence function.

Brian’s in-depth knowledge of the regulatory landscape is rooted in a diverse career spanning roles in regulated industry and at the FDA, including: Policy analyst within FDA’s Office of the Commissioner; VP of Regulatory Policy at Alkermes; Executive Director of Global Regulatory & Development Policy at Novartis; and Associate Director, Regulatory Policy, at Merck. Brian is an active member of the FDA Alumni Association (FDAAA) and serves on the organization’s Board of Directors. Learn more about Brian